0001179110-16-027490.txt : 20160706 0001179110-16-027490.hdr.sgml : 20160706 20160706174447 ACCESSION NUMBER: 0001179110-16-027490 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160701 FILED AS OF DATE: 20160706 DATE AS OF CHANGE: 20160706 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Knopf John L CENTRAL INDEX KEY: 0001586745 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 161754872 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2016-07-01 0 0001280600 ACCELERON PHARMA INC XLRN 0001586745 Knopf John L 128 SIDNEY STREET CAMBRIDGE MA 02139 1 1 0 0 CEO and President Common Stock 2016-07-01 4 M 0 23022 5.28 A 147106 D Common Stock 2016-07-01 4 S 0 7396 34.18 D 139710 D Common Stock 2016-07-01 4 S 0 20626 34.92 D 119084 D Common Stock 2016-07-05 4 M 0 30501 5.28 A 149585 D Common Stock 2016-07-05 4 S 0 28111 33.18 D 121474 D Common Stock 2016-07-05 4 S 0 2390 34.22 D 119084 D Common Stock 2016-07-06 4 M 0 41477 5.28 A 160561 D Common Stock 2016-07-06 4 S 0 31040 33.58 D 129521 D Common Stock 2016-07-06 4 S 0 10437 34.26 D 119084 D Option to Purchase Common Stock 5.28 2016-07-01 4 M 0 23022 0 D 2022-11-13 Common Stock 23022 114478 D Option to Purchase Common Stock 5.28 2016-07-05 4 M 0 30501 0 D 2022-11-13 Common Stock 30501 83977 D Option to Purchase Common Stock 5.28 2016-07-06 4 M 0 41477 0 D 2022-11-13 Common Stock 41477 42500 D The reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.63 to $34.62, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.63 to $35.29, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.98, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.01 to $34.38, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.99, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $34.49, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4. The options of registrant's common stock vested in equal quarterly installments over the first four years after the grant. /s/ John D. Quisel, as attorney-in-fact for John L. Knopf 2016-07-06